OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 04:30 pm EST
Share
OpGen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.699022 million compared to USD 0.448713 million a year ago. Net loss was USD 4.06 million compared to USD 14.1 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 5.92 a year ago. Diluted loss per share from continuing operations was USD 0.46 compared to USD 5.92 a year ago.
For the nine months, revenue was USD 2.35 million compared to USD 1.89 million a year ago. Net loss was USD 15.63 million compared to USD 26.75 million a year ago. Basic loss per share from continuing operations was USD 2.38 compared to USD 11.4 a year ago. Diluted loss per share from continuing operations was USD 2.38 compared to USD 11.4 a year ago.
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Companyâs product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Companyâs subsidiaries include Curetis GmbH and Ares Genetics GmbH.
OPGEN, INC. 
